OCC - Othocell, not approved in US
. 75MM MKT CAP
. Revenue down past 3 years, down 24% yr/yr
. 21% total return over last 3 years
. Highly paid CEO
NXS - Next Science Limited
. Thinly traded ADR on US OSX
. 175MM MKT CAP
. 500k revenues
. Other than selling more wound gel, where does. growth come from?
4DX - 4D Medical LTD
. IPO on ASX in August 2020
. 1.2MM sales, 21MM loss 2020
. Has just begun clinical trials in US so we'll see. where their expenses go once those are ongoing.
BD1 - Bard1 Life Sciences
. 67MM MKT CAP
. 600K Revenue
. Latest news I could find was 2019
PNV has been discussed here ad nauseam so I won't bother with it.
None of these has anywhere near what Avita currently has on it's plate. But when you compare revenues, expenses and losses, it wouldn't appear any of them are managing resources as well as Avita.
OCC - Othocell, not approved in US. 75MM MKT CAP. Revenue down...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.69 |
Change
-0.090(3.24%) |
Mkt cap ! $161.9M | |||
| Open | High | Low | Value | Volume |
| $2.76 | $2.76 | $2.66 | $1.483M | 545.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 8219 | $2.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.69 | 4955 | 1 |
View Market Depth
| Last trade - 16.10pm 23/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.69 |
Change
-0.090 ( 3.87 %) |
||||
| Open | High | Low | Volume | ||
| $2.74 | $2.75 | $2.67 | 20779 | ||
| Last updated 15.42pm 23/04/2024 ? | |||||
| AVH (ASX) Chart |